New systemic therapies for psoriasis.

@article{Mansouri2015NewST,
  title={New systemic therapies for psoriasis.},
  author={Yasaman Mansouri and Gary Goldenberg},
  journal={Cutis},
  year={2015},
  volume={95 3},
  pages={155-60}
}
Over the last decade, expanded understanding of psoriasis pathogenesis has led to the development of new systemic agents such as biological drugs that have revolutionized the treatment of psoriasis. Small molecule inhibitors also have been studied and offer patients options for oral administration. This article reviews recently approved and in-the-pipeline biologics (IL-17 inhibitors and IL-23 blockers) as well as small molecule inhibitors (phosphodiesterase 4 [PDE4] and Janus kinase [Jak… CONTINUE READING

From This Paper

Topics from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

C Paul, J Crowley, J Cather
Poster presented at: 73rd Annual Meeting of the American Academy of Dermatology; March 21-25, • 2014

MK-3222, an anti– IL-23p19 humanized monoclonal antibody, provides significant improvement in psoriasis over 52 weeks of treatment that is maintained after discontinuation of dosing

RGB Langley, D Thaci, KA Papp
Poster presented at: 73rd Annual Meeting of the American Academy of Dermatology; March 21-25, • 2014

New and emerging therapies in psoriasis.

Seminars in cutaneous medicine and surgery • 2014

Similar Papers

Loading similar papers…